

G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:19:40 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 597 TO ITERATE

100.0% PROCESSED 597 ITERATIONS 42 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 10475 TO 13405
 PROJECTED ANSWERS: 452 TO 1228

L2 42 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 16:19:49 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 12281 TO ITERATE

100.0% PROCESSED 12281 ITERATIONS 605 ANSWERS
 SEARCH TIME: 00.00.01

L3 605 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
161.33	161.54

<06/15/2005>

Habte

FILE 'CAPLUS' ENTERED AT 16:19:54 ON 15 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2005 VOL 142 ISS 25
FILE LAST UPDATED: 14 Jun 2005 (20050614/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 9 L3


=> d ibib abs hitstr tot

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:802568 CAPLUS
 DOCUMENT NUMBER: 141:296050
 TITLE: Preparation of 1-alkylsulfonylheterocyclylbenzazoles and related compounds as 5-hydroxytryptamine-6 ligands
 INVENTOR(S): Kelly, Michael Gerard; Cole, Derek Cecil
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 3,015, abandoned.
 CODEN: USXKCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004192749	A1	20040930	US 2004-759595	20040116
US 2002115670	A1	20020822	US 2001-3015	20011101
US 2004087595	A1	20040506	US 2003-727956	20031204
US 2004132741	A1	20040708	US 2003-728330	20031204
PRIORITY APPLN. INFO.:			US 2000-245118P	P 20001102
			US 2001-3015	B2 20011101


OTHER SOURCE(S): HARPAT 141:296050
 GI



AB Title compds. I [A = C, CR10, N; X = CR11, N; Y = CR7, N with the proviso that when X = N, then Y = CR7; Z = (CR5R6)m; W = (R9)n; R1 = H, alkylcarbonyl, alkylcarbonyloxy, etc.; R2, R3, R4, R5, R6 = H, halo, OH,

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 etc.; R7, R11 = H, halo, alkyl, etc.; R8 = alkyl, (un)substituted aryl, heteroaryl; R9 = H, halo, alkyl, etc.; R10 = H, OH, (un)substituted alkyl; m = 1-3; n = 0-3] and their pharmaceutically acceptable salts were prepd. For example, condensation of 2-methylthio-2-imidazoline hydroiodide and amine II, e.g., prepd. from 1H-indol-4-ylpiperazine in 3-steps, afforded piperazine III. In 5-HT6 binding affinity assays, 53-examples of compds. I exhibited Ki values ranging from 0.3-306 nM, e.g., the Ki of piperazine III was 24 nM. Of note, compds. I demonstrated up to a 50-fold selectivity for the 5-HT6 receptor when compared to their affinity at the 5-HT7 receptor (sic). Compds. I are claimed useful for the treatment of disorders related to or affected by the 5-HT6 receptor, e.g., motor, anxiety and cognitive disorders.
 IT 393508-47-9P, 1-(Phenylsulfonyl)-4-piperazin-1-yl-1H-indole hydrochloride 423174-76-9P 423174-78-1P 423174-79-2P 423174-82-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of alkylsulfonylheterocyclylbenzazoles and related compds.)


as 5-hydroxytryptamine-6 ligands)
 RN 393508-47-9 CAPLUS
 CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 423174-76-9 CAPLUS
 CN 1H-Indazole, 4-[4-(phenylmethyl)-1-piperazinyl]-1-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 423174-78-1 CAPLUS
 CN 1H-Indazole, 4-[4-(phenylmethyl)-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 423174-79-2 CAPLUS
 CN 1H-Indazole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 423174-82-7 CAPLUS
 CN 1H-Indazole, 4-[4-(2-phenylethyl)-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



IT 423174-09-8P 423174-10-1P 423174-11-2P
 423174-13-4P 423174-15-6P 423174-17-8P
 423174-19-0P 423174-21-4P 423174-23-6P
 423174-25-8P 423174-27-0P 423174-29-2P
 423174-31-6P 423174-33-8P 423174-35-0P
 423174-37-2P 423174-39-4P 423174-41-8P
 423174-43-0P 423174-45-2P 423174-47-4P
 423174-48-5P 423174-50-9P 423174-52-1P
 423174-54-3P 423174-56-5P 423174-57-6P
 423174-58-7P 423174-59-8P 423174-61-2P
 423174-63-4P 423174-65-6P 423174-66-7P
 423174-67-8P 423174-68-9P 423174-69-0P
 423174-71-4P 423174-72-5P 423174-73-6P
 423174-74-7P 423174-81-6P 423174-84-9P
 423174-85-0P 423174-87-2P 423174-89-4P
 423174-90-7P 423174-91-8P 423174-93-0P
 423174-94-1P 423174-95-2P 423174-96-3P
 423174-97-4P 423174-98-5P 423175-00-2P

<06/15/2005>

Habte

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


423175-03-5P 423175-12-2P 423175-18-2P
 423175-31-9P 423175-33-1P 423175-36-4P
 423722-47-8P 431044-50-7P 431045-45-3P
 756469-52-0P 765271-25-8P 765273-28-7P
 765273-29-8P 765273-30-1P 765273-31-2P
 765273-32-3P 765273-33-4P 765273-34-5P
 765273-35-6P 765273-36-7P 765273-37-8P
 765273-38-9P 765273-39-0P 765273-40-3P
 765273-41-4P 765273-42-5P 765273-43-6P
 765273-44-7P 765273-45-8P 765273-46-9P
 765273-47-0P 765273-48-1P 765273-49-2P
 765273-50-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of alkylsulfonylheterocyclylbenzazoles and related compds. as 5-hydroxytryptamine-6 ligands)

RN 423174-09-8 CAPLUS


CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[(4,5-dihydro-1H-imidazol-2-yl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 423174-10-1 CAPLUS


CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[(4,5-dihydro-1H-imidazol-2-yl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 423174-11-2 CAPLUS


CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[(4,5-dihydro-1H-imidazol-2-yl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 423174-13-4 CAPLUS


CN 1H-Indole, 4-[(4,5-dihydro-1H-imidazol-2-yl)-1-piperazinyl]-1-[(3,4-dimethoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-15-6 CAPLUS

CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(4,5-dihydro-1H-imidazol-2-yl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 423174-17-8 CAPLUS


CN 1H-Indole, 4-[(4-(phenylmethyl)-1-piperazinyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 423174-19-0 CAPLUS

CN 1H-Indole, 4-[(5-chloro-2-thienyl)methyl]-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 423174-21-4 CAPLUS


CN 1H-Indole, 4-[(3-nitrophenyl)methyl]-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 423174-23-6 CAPLUS

CN Piperazine, 1-acetyl-4-[1-(phenylsulfonyl)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-25-8 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-27-0 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[4-[(5-chloro-2-thienyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-33-8 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-35-0 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[4-[(5-chloro-2-thienyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-29-2 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[4-[(3-nitrophenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-31-6 CAPLUS
 CN Piperazine, 1-acetyl-4-[1-[(2-bromophenyl)sulfonyl]-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-37-2 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[4-[(3-nitrophenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-39-4 CAPLUS
 CN Piperazine, 1-acetyl-4-[1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-41-8 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-[(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-43-0 CAPLUS
 CN 1H-Indole, 4-[4-[(5-chloro-2-thienyl)methyl]-1-piperazinyl]-1-[(3,4-dimethoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 423174-48-5 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(4-(phenylmethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423174-50-9 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423174-52-1 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(5-chloro-2-thienyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-45-2 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-[(3-nitrophenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-47-4 CAPLUS
 CN Piperazine, 1-acetyl-4-[1-[(3,4-dimethoxyphenyl)sulfonyl]-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-54-3 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(3-nitrophenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-56-5 CAPLUS
 CN 1H-Indole, 4-[4-[(3-methoxyphenyl)methyl]-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-57-6 CAPLUS
 CN 1H-Indole, 1-(phenylsulfonyl)-4-[(4-(4-pyridinylmethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423174-58-7 CAPLUS
 CN 1H-Indole, 1-(phenylsulfonyl)-4-[(4-(3-pyridinylmethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-63-4 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[(4-(3-pyridinylmethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423174-65-6 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[(4-(3-methoxyphenyl)methyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-59-8 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[(4-(3-methoxyphenyl)methyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-61-2 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[(4-(4-pyridinylmethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-66-7 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[(4-(4-pyridinylmethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423174-67-8 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[(4-(3-pyridinylmethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-68-9 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-[(3-methoxyphenyl)methyl]-1-piperazinyl- (9CI) (CA INDEX NAME)




RN 423174-69-0 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-[(4-pyridinyl)methyl]-1-piperazinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-73-6 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(4-pyridinyl)methyl]-1-piperazinyl- (9CI) (CA INDEX NAME)




RN 423174-74-7 CAPLUS
 CN 1H-Indazole, 4-[4-(2-phenylethyl)-1-piperazinyl]-1-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-71-4 CAPLUS
 CN 1H-Indazole, 4-[4-(2-phenylethyl)-1-piperazinyl]-1-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 423174-72-5 CAPLUS
 CN 1H-Indazole, 4-[4-(2-phenylethyl)-1-piperazinyl]-1-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 423174-81-6 CAPLUS
 CN 1H-Indazole, 4-[4-(2-phenylethyl)-1-piperazinyl]-1-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 423174-84-9 CAPLUS
 CN 1H-Indazole, 4-[4-(2-phenylethyl)-1-piperazinyl]-1-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 423174-85-0 CAPLUS
 CN 1H-Indazole, 4-[4-(4-fluorophenyl)-4-oxobutyl]-1-piperazinyl-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


PAGE 1-A




PAGE 2-A

RN 423174-87-2 CAPLUS
 CN 1H-Indazole, 4-[4-(2-oxo-2-phenylethyl)-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-89-4 CAPLUS
 CN 1H-Indazole, 4-[4-(3-phenylpropyl)-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 423174-90-7 CAPLUS
 CN 1H-Indazole, 1-(phenylsulfonyl)-4-[4-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)]


L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 423174-91-8 CAPLUS
 CN 1H-Indazole, 1-[(2-phenylethyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-93-0 CAPLUS
 CN 1H-Indazole, 1-[(4-fluorophenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-94-1 CAPLUS

Habte

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1H-Indazole, 1-[(4-chlorophenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-95-2 CAPLUS
 CN 1H-Indazole, 1-[(4-methoxyphenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-96-3 CAPLUS
 CN 1H-Indazole, 4-[4-(phenylmethyl)-1-piperazinyl]-1-[[4-(trifluoromethoxy)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-97-4 CAPLUS
 CN 1H-Indazole, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-98-5 CAPLUS
 CN 1H-Indazole, 1-[(4-methylphenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423175-00-2 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-5-(1-piperazinyl)-, hydrochloride (9CI) (CA INDEX NAME)




• x HCl

RN 423175-03-5 CAPLUS
 CN 1H-Indole, 1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-12-6 CAPLUS
 CN 1H-Indole, 1-[(4-butoxyphenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423175-18-2 CAPLUS
 CN 1H-Indole, 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 423175-31-9 CAPLUS
 CN 1H-Indole, 1-(2-naphthalenylsulfonyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-33-1 CAPLUS
 CN 1H-Indole, 5-(1-piperazinyl)-1-[[4-(trifluoromethoxy)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 423175-36-4 CAPLUS
 CN 1H-Indole, 1-[(4-iodophenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423722-47-8 CAPLUS
 CN 1H-Indazole, 1-[(naphthalenylsulfonyl)-4-(4-(phenylmethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)]




RN 431044-50-7 CAPLUS
 CN 1H-Indazole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 765273-28-7 CAPLUS
 CN 1H-Indazole, 1-(phenylsulfonyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 765273-29-8 CAPLUS
 CN 1H-Indazole, 1-(phenylsulfonyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 765273-30-1 CAPLUS
 CN 1H-Indazole, 1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 765273-31-2 CAPLUS
 CN 1H-Indazole, 1-[(2-bromophenyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 431045-45-3 CAPLUS
 CN 1H-Indazole, 1-[(2-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 756469-52-0 CAPLUS
 CN 1H-Indazole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 765271-25-8 CAPLUS
 CN 1H-Indazole, 1-[(4-aminophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 765273-32-3 CAPLUS
 CN 1H-Indazole, 1-[(4-bromophenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 765273-33-4 CAPLUS
 CN 1H-Indazole, 1-[(4-bromophenyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 765273-34-5 CAPLUS
 CN 1H-Indazole, 1-[(5-bromo-2-thienyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 765273-35-6 CAPLUS
 CN 1H-Indazole, 1-[(5-bromo-2-thienyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 765273-36-7 CAPLUS
 CN 1H-Indazole, 1-[(4-butoxyphenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)


<06/15/2005>

Habte


L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 765273-37-8 CAPLUS
CN 1H-Indazole, 1-[(4-butoxyphenyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 765273-38-9 CAPLUS
CN 1H-Indazole, 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 765273-39-0 CAPLUS
CN 1H-Indazole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 765273-40-3 CAPLUS
CN 1H-Indazole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 765273-45-8 CAPLUS
CN 1H-Indazole, 1-[(4-methoxyphenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 765273-46-9 CAPLUS
CN 1H-Indazole, 1-[(2-naphthalenyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 765273-47-0 CAPLUS
CN 1H-Indazole, 1-[(4-(trifluoromethoxy)phenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 765273-48-1 CAPLUS
CN 1H-Indazole, 6-(1-piperazinyl)-1-[(4-(trifluoromethoxy)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 765273-41-4 CAPLUS
CN 1H-Indazole, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 765273-42-5 CAPLUS
CN 1H-Indazole, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 765273-43-6 CAPLUS
CN 1H-Indazole, 1-[(4-fluorophenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 765273-44-7 CAPLUS
CN 1H-Indazole, 1-[(4-fluorophenyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 765273-49-2 CAPLUS
CN 1H-Indazole, 1-[(4-iodophenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 765273-50-5 CAPLUS
CN 1H-Indazole, 1-[(4-iodophenyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




IT 393508-48-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of alkylsulfonylheterocyclbenzazoles and related compds.)

as 5-hydroxytryptamine-6 ligands)

RN 393508-48-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(phenylsulfonyl)-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:977788 CAPLUS
DOCUMENT NUMBER: 138:55865
TITLE: Preparation of 4-piperazinylindoles with 5-HT6 receptor affinity
INVENTOR(S): Briggs, Andrew John; Clark, Robin Douglas; Harris, Ralph New, III; Repke, David Bruce; Wren, Douglas Leslie
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002102774	A1	20021227	WO 2002-EP6201	20020606
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2450245	AA	20021227	CA 2002-2450245	20020606
EP 1401812	A1	20040331	EP 2002-780760	20020606
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002010411	A	20040817	BR 2002-10411	20020606
JP 2005501019	T2	20050113	JP 2003-505317	20020606
US 2003045527	A1	20030306	US 2002-172360	20020614
US 6790848	B2	20040914		
PRIORITY APPL. INFO.:			US 2001-298834P	P 20010615
			US 2002-378748P	P 20020508
			WO 2002-EP6201	W 20020606
OTHER SOURCE(S):		MARPAT 138:55865		
GI				



L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB The title compds. [I: R1 = H, halo, haloalkyl, alkyl; R2 = H, alkyl, alkoxy, alkylthio; R3 = SO2Ar; Ar = (un)substituted aryl, heteroaryl; R4 = H, halo, alkyl, etc.; R5 = H, CH2Ph, alkyl] and their pharmaceutically acceptable salts have generally 5-HT6 receptor affinity, were prepared and formulated. E.g., a 3-step synthesis of 1.HCl [R1, R2 = H; R3 = naphthalene-1-sulfonyl; R4, R5 = H], starting with 4-nitro-1H-indole and naphthalene-1-sulfonyl chloride, which showed pKi of 9.8 against 5-HT6 receptor binding, was given.

IT 393508-47-9P 412048-52-3P 412048-56-7P
412048-93-2P 412048-95-4P 412048-98-7P
412049-05-9P 412049-45-7P 412049-61-7P
412049-71-9P 412049-72-0P 423175-42-2P
431043-51-5P 431043-52-6P 431043-57-1P
431043-60-6P 431043-89-9P 431043-91-3P
431043-92-4P 431044-30-3P 431044-64-3P
431044-65-4P 431044-66-3P 431044-67-6P
431045-30-6P 431045-35-1P 431045-37-3P
431045-39-5P 431045-41-9P 431045-42-0P
479080-52-9P 479080-53-0P 479080-54-1P
479080-55-2P 479080-56-3P 479080-57-4P
479080-58-5P 479080-62-1P 479080-66-5P
479080-67-6P 479080-68-7P 479080-69-8P
479080-70-1P 479080-74-5P 479080-75-6P
479080-76-7P 479080-77-8P 479080-78-9P
479080-79-0P 479080-80-3P 479080-81-4P
479080-82-5P 479080-83-6P 479080-84-7P
479080-85-8P 479080-86-9P 479080-87-0P
479080-88-1P 479080-89-2P 479081-00-0P
479081-01-1P 479081-02-2P 479081-03-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-piperazinylindoles with 5-HT6 receptor affinity)
RN 393508-47-9 CAPLUS
CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412048-52-3 CAPLUS

<06/15/2005>


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN 1H-Indole, 1-(1-naphthalenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-56-7 CAPLUS
CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 412048-93-2 CAPLUS
CN 1H-Indole, 1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 412048-95-4 CAPLUS
 CN 1H-Indole, 4-((1-piperazinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 412048-98-7 CAPLUS
 CN 1H-Indole, 1-[(3-cyanophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412049-05-9 CAPLUS
 CN 1H-Indole, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 412049-71-9 CAPLUS
 CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 412049-72-0 CAPLUS
 CN 1H-Indole, 1-[(2,5-dimethoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-42-2 CAPLUS
 CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431043-51-5 CAPLUS
 CN 1H-Indole, 1-[(2,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 412049-45-7 CAPLUS
 CN 1H-Indole, 2-methyl-1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412049-61-7 CAPLUS
 CN 1H-Indole, 4-((1-piperazinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431043-52-6 CAPLUS
 CN 1H-Indole, 1-[(2,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431043-51-5
 CMF C18 H17 C12 N3 O2 S




CH 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 431043-57-1 CAPLUS
 CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431043-60-6 CAPLUS
 CN 1H-Indole, 1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 412048-93-2
 CMF C18 H19 Cl N3 O2 S



CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 431043-89-9 CAPLUS
 CN 1H-Indole, 1-[(2-fluorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 431044-30-3 CAPLUS
 CN 1H-Indole, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1-piperazinyl)-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 412049-05-9
 CMF C16 H19 N5 O2 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 431044-64-3 CAPLUS
 CN 1H-Indole, 1-[(3-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431043-91-3 CAPLUS
 CN 1H-Indole, 1-[(3-fluorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)

CM 1


CRN 431043-91-3
 CMF C18 H18 F N3 O2 S




RN 431043-92-4 CAPLUS
 CN 1H-Indole, 1-[(3-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-91-3
 CMF C18 H18 F N3 O2 S




L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431044-65-4 CAPLUS
 CN 1H-Indole, 1-[(3-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-64-3
 CMF C19 H21 N3 O3 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 431044-66-5 CAPLUS
 CN 1H-Indole, 1-[(2,6-difluorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431044-67-6 CAPLUS
 CN 1H-Indole, 1-[(2,6-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-66-5
 CMF C18 H17 F2 N3 O2 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 431045-30-6 CAPLUS
 CN 1H-Indole, 1-[(3-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-41-9 CAPLUS
 CN 1H-Indole, 4-(1-piperazinyl)-1-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 431045-42-0 CAPLUS
 CN 1H-Indole, 1-[(3,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 479080-52-9 CAPLUS
 CN 1H-Indole, 1-[(3,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-35-1 CAPLUS
 CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-37-3 CAPLUS
 CN 1H-Indole, 1-[(1-naphthalenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-39-5 CAPLUS
 CN 1H-Indole, 1-[(4-(1,1-dimethylethyl)phenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 479080-53-0 CAPLUS
 CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 479080-54-1 CAPLUS
 CN 1H-Indole, 1-[(3-bromophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 479080-55-2 CAPLUS
 CN 1H-Indole, 4-[(1-piperazinyl)-1-(2-thienylsulfonyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431045-41-9
 CMF C16 H17 N3 O2 S2



CH 2


CRN 76-05-1
 CMF C2 H F3 O2



L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 479080-58-5 CAPLUS
 CN 1H-Indole, 1-[[4-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 479080-57-4
 CMF C19 H21 N3 O4 S2



CH 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 479080-62-1 CAPLUS
 CN 1H-Indole, 1-[[2,5-dimethoxyphenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 412049-72-0
 CMF C20 H23 N3 O4 S




<06/15/2005>

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 479080-56-3 CAPLUS
 CN 1H-Indole, 1-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431045-39-5
 CMF C22 H27 N3 O2 S




CH 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 479080-57-4 CAPLUS
 CN 1H-Indole, 1-[[4-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CH 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 479080-66-5 CAPLUS
 CN 1H-Indole, 1-[[3-(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431045-35-1
 CMF C18 H18 Cl N3 O2 S



CH 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 479080-67-6 CAPLUS
 CN 1H-Indole, 1-[[3-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 479080-68-7 CAPLUS
 CN 1H-Indole, 1-[(3-(methylsulfonyl)phenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 479080-67-6
 CMF C19 H21 N3 O4 S2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 479080-69-8 CAPLUS
 CN 1H-Indole, 1-[(5-bromo-6-chloro-3-pyridinyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 479080-75-6 CAPLUS
 CN 1H-Indole, 1-[(5-bromo-6-chloro-3-pyridinyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 479080-74-5
 CMF C17 H16 Br Cl N4 O2 S



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 479080-76-7 CAPLUS
 CN Benzenesulfonamide, N,N-dimethyl-3-[(4-(1-piperazinyl)-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)

<06/15/2005>


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 479080-70-1 CAPLUS
 CN 1H-Indole, 1-[(3-bromo-5-(methylsulfonyl)phenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 479080-69-8
 CMF C19 H20 Br N3 O4 S2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 479080-74-5 CAPLUS
 CN 1H-Indole, 1-[(5-bromo-6-chloro-3-pyridinyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 479080-77-8 CAPLUS
 CN Benzenesulfonamide, N-cyclopropyl-3-[(4-(1-piperazinyl)-1H-indol-1-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 479080-78-9 CAPLUS
 CN 1H-Indole, 1-[(2-fluoro-5-(methylsulfonyl)phenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 479080-79-0 CAPLUS
 CN 1H-Indole, 1-[(2-fluoro-5-(methylsulfonyl)phenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 479080-78-9
 CMF C19 H20 F N3 O4 S2

Habte


L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2RN 479080-80-3 CAPLUS
CN 1H-Indole, 1-[(3-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1


CRN 412048-98-7
CMF C19 H18 N4 O2 S

CH 2


CRN 76-05-1

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CMF C2 H F3 O2RN 479080-83-6 CAPLUS
CN 1H-Indole, 1-[[2-[(2-methylpropyl)sulfonyl]phenyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


CH 1

CRN 479080-83-6
CMF C22 H27 N3 O4 S2

CH 2

CRN 76-05-1
CMF C2 H F3 O2L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CMF C2 H F3 O2RN 479080-81-4 CAPLUS
CN 1H-Indole, 1-[[2-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)RN 479080-82-5 CAPLUS
CN 1H-Indole, 1-[[2-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 479080-81-4
CMF C19 H21 N3 O4 S2


CH 2

CRN 76-05-1

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 479080-85-8 CAPLUS
CN 1H-Indole, 1-[[3-(ethylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


● HCl

RN 479080-86-9 CAPLUS
CN 1H-Indole, 4-(1-piperazinyl)-1-[[3-(propylsulfonyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)RN 479080-87-0 CAPLUS
CN 1H-Indole, 4-(1-piperazinyl)-1-[[3-(propylsulfonyl)phenyl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 479080-86-9
CMF C21 H25 N3 O4 S2

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





CH 2

CRN 76-05-1
CMF C2 H F3 O2RN 479080-88-1 CAPLUS
CN 1H-Indole, 3-bromo-1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


● HCl

RN 479080-89-2 CAPLUS
CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 479081-02-2 CAPLUS
CN 1H-Indole, 3-bromo-1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)RN 479081-03-3 CAPLUS
CN 1H-Indole, 4-(1-piperazinyl)-1-[(3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)IT 393508-48-0P 479080-94-9P 479080-95-0P
479080-96-1P 479080-98-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-piperazinylindoles with 5-HT6 receptor affinity)
RN 393508-48-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(phenylsulfonyl)-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 479081-00-0 CAPLUS
CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)RN 479081-01-1 CAPLUS
CN 1H-Indole, 1-[(3-(ethylsulfonyl)phenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 479080-94-9 CAPLUS
CN 1H-Indole, 1-[(3,5-dichlorophenyl)sulfonyl]-4-(4-(phenylmethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)RN 479080-95-0 CAPLUS
CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-4-(4-(phenylmethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)RN 479080-96-1 CAPLUS
CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-4-(4-(phenylmethyl)-1-

Habte

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
piperazinyl]- (9CI) (CA INDEX NAME)



RN 479080-98-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-bromo-1-(phenylsulfonyl)-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:575065 CAPLUS
DOCUMENT NUMBER: 137:140776
TITLE: Preparation of piperidinyl and piperazinyl amino acid derivatives as melanocortin receptor agonists
INVENTOR(S): Backer, Ryan Thomas; Briner, Karin; Doecke, Christopher William; Fisher, Matthew Joseph; Kuklish, Steven Lee; Mancuso, Vincent; Martinelli, Michael John; Mullaney, Jeffrey Thomas; Xie, Chaoyu
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 263 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059107	A1	20020801	WO 2002-US516	20020123
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2433025	AA	20020801	CA 2002-2433025	20020123
EP 1368339	A1	20031210	EP 2002-701923	20020123
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, HK, CY, AL, TR			
JP 2004521117	T2	20040715	JP 2002-559409	20020123
US 2004058936	A1	20040325	US 2003-466249	20030711
PRIORITY APPLN. INFO.:			US 2001-263595P	P 20010123
			WO 2002-US516	W 20020123
OTHER SOURCE(S):			CASREACT 137:140776; MARPAT 137:140776	
GI				




L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
AB The invention relates to melanocortin receptor (MC-R) agonists I [G = CR1 or N; L1 = H2 or oxo; T = isoquinolinyl or tetrahydro derivative, isoindolinyl, or piperazinyl; n = 0-8; R = H, OH, CN, NO2, halo, alkyl, acyl, etc.; R1 = H, alkyl, alkylcarbamoyl, (D)phenyl, (D)cycloalkyl, or oxo (unless amide is formed); p = 0-4; CR2CR2 is a 5- or 6-membered carbocycle optionally substituted by 1-3 groups R; R3 = (un)substituted aryl or thienyl; R4 = H, alkyl, acyl, cycloalkyl, or alkoxyalkyl], or their pharmaceutically-acceptable salts or stereoisomers, which are useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction. Comps. I comprise three domains, i.e., a piperidino or piperazinyl fragment, an amino acid, and a radical CLL(CH2)n-T. Thus, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid [1-(4-chlorobenzyl)-2-[4-[2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl]piperazin-1-yl]-2-oxoethyl]amide (claimed compound) was prepared via acylation of the piperazine moiety.

IT 444619-56-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinyl and piperazinyl amino acid derivs. as melanocortin receptor agonists)

RN 444619-56-1 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-[2,3-dihydro-1-(methylsulfonyl)-1H-indol-7-yl]-1-piperazinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 444620-56-8P 444620-77-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of piperidinyl and piperazinyl amino acid derivs. as melanocortin receptor agonists)

RN 444620-56-8 CAPLUS
CN 1H-Indole, 2,3-dihydro-1-(methylsulfonyl)-7-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 444620-77-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2,3-dihydro-1-(methylsulfonyl)-1H-indol-7-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:408522 CAPLUS
 DOCUMENT NUMBER: 136:401783
 TITLE: Preparation of 4-piperazinoindoles for treating CNS disorders
 INVENTOR(S): Bromidge, Steven Mark
 PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
 SOURCE: PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002041889	A2	20020530	WO 2001-EP13411	20011116
WO 2002041889	A3	20030410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HL, HR, NE, SN, TD, TG				
AU 2002020715	A5	20020603	AU 2002-20715	20011116
EP 1335722	A2	20030820	EP 2001-997304	20011116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517072	T2	20040610	JP 2002-544069	20011116
PRIORITY APPLN. INFO.: GB 2000-28708 A 20001124 GB 2001-13517 A 20010604 WO 2001-EP13411 W 20011116				

OTHER SOURCE(S): MARPAT 136:401783
 GI


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




AB The title compds. [I; P = Ph, naphthyl, heteroaryl; R1 = halo, alkyl, alkoxy, etc.; R2 = halo, alkyl, cycloalkyl, etc.; R3 = (un)substituted 5-7 membered (bicyclic) heterocyclic ring containing 1-3 heteroatoms selected from N, S or O; m = 0-4; n = 0-5] and their pharmaceutically acceptable salts which have 5-HT6 receptor activity, were prepared. Thus, reacting 4-(4-benzylpiperazin-1-yl)-1H-indole with 5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl chloride (44t) followed by deprotection (69t) afforded II. All exemplified compds. I were found to have a pKi of 7.0-9.7 at human cloned 5-HT6 receptors.

IT 431045-02-2P 431045-04-4P 431045-05-5P
 431045-06-6P 431045-07-7P 431045-08-8P
 431045-09-9P 431045-10-2P 431045-11-3P
 431045-12-4P 431045-13-5P 431045-14-6P
 431045-15-7P 431045-16-8P 431045-17-9P
 431045-18-0P 431045-19-1P 431045-20-4P
 431045-21-5P 431045-22-6P 431045-23-7P
 431045-24-8P 431045-25-9P 431045-26-0P
 431045-27-1P 431045-28-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 4-piperazinoindoles for treating CNS disorders)
 RN 431045-02-2 CAPLUS
 CN 1H-Indole, 1-[(4-methylphenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-04-4 CAPLUS
 CN 1H-Indole, 1-[(5-chloro-2-naphthalenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-05-5 CAPLUS
 CN 1H-Indole, 1-[(3-bromophenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 431045-06-6 CAPLUS
 CN 1H-Indole, 1-[(2,5-dichloro-3-thienyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-07-7 CAPLUS
 CN 1H-Indole, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 431045-08-8 CAPLUS
 CN 1H-Indole, 1-[(4-bromo-5-chloro-2-thienyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-09-9 CAPLUS
 CN 1H-Indole, 1-[(5-chloro-1-naphthalenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


<06/15/2005>

Habte


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-10-2 CAPLUS
CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI)
(CA INDEX NAME)




RN 431045-11-3 CAPLUS
CN 1H-Indole, 1-[(3-chloro-4-methylphenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-12-4 CAPLUS

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 431045-15-7 CAPLUS
CN 1H-Indole, 1-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 431045-16-8 CAPLUS
CN 1H-Indole, 4-(4-methyl-1-piperazinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 431045-17-9 CAPLUS
CN 1H-Indole, 4-(4-methyl-1-piperazinyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




<06/15/2005>


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Indole, 1-[(4-bromophenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI)
(CA INDEX NAME)



RN 431045-13-5 CAPLUS
CN 1H-Indole, 4-(4-methyl-1-piperazinyl)-1-(1-naphthalenylsulfonyl)- (9CI)
(CA INDEX NAME)




RN 431045-14-6 CAPLUS
CN 1H-Indole, 4-(4-methyl-1-piperazinyl)-1-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 431045-18-0 CAPLUS
CN 1H-Indole, 4-(4-methyl-1-piperazinyl)-1-[(3-nitrophenyl)sulfonyl]- (9CI)
(CA INDEX NAME)



RN 431045-19-1 CAPLUS
CN 1H-Indole, 1-[(3-bromo-5-chloro-2-thienyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-20-4 CAPLUS
CN 1H-Indole, 1-[(3-cyanophenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI)
(CA INDEX NAME)




Habte

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 431045-21-5 CAPLUS
 CN 1H-Indole, 4-(4-methyl-1-piperazinyl)-1-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 431045-22-6 CAPLUS
 CN 1H-Indole, 1-[(3,5-dichlorophenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-23-7 CAPLUS
 CN 1H-Indole, 1-[(3-chloro-4-fluorophenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 431045-24-8 CAPLUS
 CN 1H-Indole, 1-[(2-dibenzofuranylsulfonyl)-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-25-9 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-26-0 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-27-1 CAPLUS
 CN 1H-Indole, 1-[(3-chloro-2-methylphenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 431045-28-2 CAPLUS
 CN 1H-Indole, 4-(4-methyl-1-piperazinyl)-1-(2-naphthalenylsulfonyl)- (9CI)

<06/15/2005>

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 412048-92-1P 412048-95-4P 412048-98-7P
 412049-71-9P 412043-42-4P 412043-43-5P
 412043-45-7P 412043-47-9P 412043-49-1P
 412043-52-6P 412043-55-9P 412043-58-2P
 412043-60-6P 412043-63-9P 412043-66-2P
 412043-68-4P 412043-71-9P 412043-73-1P
 412043-75-3P 412043-77-5P 412043-79-7P
 412043-81-1P 412043-83-3P 412043-86-6P
 412043-88-8P 412043-90-2P 412043-92-4P
 412043-95-7P 412043-98-0P 412044-01-8P
 412044-03-0P 412044-04-1P 412044-06-3P
 412044-08-5P 412044-09-6P 412044-11-0P
 412044-13-2P 412044-15-4P 412044-17-6P
 412044-19-8P 412044-21-2P 412044-23-4P
 412044-25-6P 412044-27-8P 412044-29-0P
 412044-30-3P 412044-32-5P 412044-34-7P
 412044-36-9P 412044-38-1P 412044-39-2P
 412044-41-6P 412044-43-8P 412044-45-0P
 412044-47-2P 412044-49-4P 412044-50-7P
 412044-51-8P 412044-53-0P 412044-55-2P
 412044-57-4P 412044-59-6P 412044-61-0P
 412044-63-2P 412044-65-4P 412044-67-6P
 412044-69-8P 412044-71-2P 412044-73-4P
 412044-74-5P 412044-76-7P 412044-78-9P
 412044-80-3P 412044-82-5P 412044-84-7P
 412044-86-9P 412044-87-0P 412044-89-2P
 412044-91-6P 412044-93-8P 412044-95-0P
 412044-97-2P 412044-99-4P 412045-01-1P
 412045-03-3P 412045-29-3P 412045-30-6P
 412045-31-7P 412045-32-0P 412045-33-9P
 412045-35-1P 412045-36-2P 412045-37-3P
 412045-38-4P 412045-39-5P 412045-40-8P
 412045-41-9P 412045-42-0P 412045-43-1P
 412045-44-2P 412045-45-3P 412045-46-4P
 412045-47-5P 412045-48-6P 412045-49-7P
 412045-50-0P 412045-51-1P 412045-52-2P
 412045-53-3P 412045-54-4P 412045-55-5P
 412045-56-6P 412045-57-7P 412045-58-8P
 412045-59-9P 412045-60-2P 412045-61-3P
 412045-62-4P 412045-63-5P 412045-64-6P
 412045-65-7P 412045-66-8P 412045-67-9P
 412045-68-0P 412045-69-1P 412045-70-4P

Habte

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


431045-71-8P 431045-72-6P 431045-73-7P
 431045-74-8P 431045-75-9P 431045-76-0P
 431045-77-1P 431045-78-2P 431045-80-6P
 431045-81-7P 431045-82-8P 431045-83-9P
 431045-84-0P 431045-85-1P 431045-86-2P
 431045-87-3P 431045-88-4P 431045-89-5P
 431045-90-6P 431045-91-9P 431045-92-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Prepn. of 4-piperazinoindoles for treating CNS disorders)


RN 412048-92-1 CAPLUS

CN 1H-Indole, 1-[(4-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412048-95-4 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[(3-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 412048-98-7 CAPLUS

CN 1H-Indole, 1-[(3-cyanophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 1

CRN 431043-42-4

CMF C21 H20 Cl N3 O2 S2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 431043-45-7 CAPLUS

CN Acetamide, N-[4-methyl-5-[(4-(1-piperazinyl)-1H-indol-1-yl)sulfonyl]-2-thiazolyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-44-6


CMF C18 H21 N5 O3 S2



CM 2


<06/15/2005>

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 412049-71-9 CAPLUS

CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 431043-42-4 CAPLUS

CN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 431043-43-5 CAPLUS

CN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-4-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 76-05-1

CMF C2 H F3 O2




RN 431043-47-9 CAPLUS

CN 1H-Indole, 1-[(pentafluorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-46-8

CMF C18 H14 F5 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 431043-49-1 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[(2,4,5-trichlorophenyl)sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431043-48-0

CMF C18 H16 Cl3 N3 O2 S

Habte

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CH 2
CRN 76-05-1
CMF C2 H F3 O2




RN 431043-52-6 CAPLUS
CN 1H-Indole, 1-[(2,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
CRN 431043-51-5
CMF C18 H17 Cl2 N3 O2 S



CH 2

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CH 2
CRN 76-05-1
CMF C2 H F3 O2



RN 431043-60-6 CAPLUS
CN 1H-Indole, 1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
CRN 412048-93-2
CMF C18 H18 Cl N3 O2 S



CH 2
CRN 76-05-1
CMF C2 H F3 O2


<06/15/2005>

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431043-55-9 CAPLUS
CN 1H-Indole, 4-(1-piperazinyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
CRN 431043-54-8
CMF C21 H25 N3 O2 S



CH 2
CRN 76-05-1
CMF C2 H F3 O2



RN 431043-58-2 CAPLUS
CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1
CRN 431043-57-1

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431043-63-9 CAPLUS
CN 1H-Indole, 1-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
CRN 431043-62-8
CMF C18 H17 Cl N4 O4 S



CH 2
CRN 76-05-1
CMF C2 H F3 O2




RN 431043-66-2 CAPLUS
CN 1H-Indole, 1-[(4-iodophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
CRN 431043-65-1
CMF C18 H18 I N3 O2 S

Habte

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CH 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 431043-68-4 CAPLUS
 CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
 CRN 423175-42-2
 CMF C19 H21 N3 O3 S



CH 2
 CRN 76-05-1

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CH 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 431043-75-3 CAPLUS
 CN 1H-Indole, 1-[(2,5-dimethylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
 CRN 431043-74-2
 CMF C20 H23 N3 O2 S



CH 2
 CRN 76-05-1
 CMF C2 H F3 O2


<06/15/2005>

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431043-71-9 CAPLUS
 CN 1H-Indole, 1-[(4-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
 CRN 431043-70-8
 CMF C19 H21 N3 O2 S



CH 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 431043-73-1 CAPLUS
 CN Benzoic acid, 2-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1
 CRN 431043-72-0
 CMF C20 H21 N3 O4 S

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431043-77-5 CAPLUS
 CN Benzoic acid, 3-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
 CRN 431043-76-4
 CMF C19 H19 N3 O4 S



CH 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 431043-79-7 CAPLUS
 CN 1H-Indole, 1-[(3,4-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
 CRN 431043-78-6
 CMF C18 H17 Cl2 N3 O2 S

Habte

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CH 2
CRN 76-05-1
CMF C2 H F3 O2




RN 431043-81-1 CAPLUS
CN 1H-Indole, 1-[(4,5-dibromo-2-thienyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
CRN 431043-80-0
CMF C16 H15 Br2 N3 O2 S2



CH 2
CRN 76-05-1

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CH 2
CRN 76-05-1
CMF C2 H F3 O2



RN 431043-88-8 CAPLUS
CN 1H-Indole, 1-[(4-bromo-2,5-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
CRN 431043-87-7
CMF C18 H16 Br F2 N3 O2 S



CH 2
CRN 76-05-1
CMF C2 H F3 O2


<06/15/2005>

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431043-83-3 CAPLUS
CN 1H-Indole, 1-[(4-ethylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
CRN 431043-82-2
CMF C20 H23 N3 O2 S



CH 2
CRN 76-05-1
CMF C2 H F3 O2



RN 431043-86-6 CAPLUS
CN 1H-Indole, 4-(1-piperazinyl)-1-[(4-propylphenyl)sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1
CRN 431043-85-5
CMF C21 H25 N3 O2 S

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431043-90-2 CAPLUS
CN 1H-Indole, 1-[(2-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
CRN 431043-89-9
CMF C18 H18 F N3 O2 S



CH 2
CRN 76-05-1
CMF C2 H F3 O2




RN 431043-92-4 CAPLUS
CN 1H-Indole, 1-[(3-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
CRN 431043-91-3
CMF C18 H18 F N3 O2 S

Habte


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CH 2
CRN 76-05-1
CMF C2 H F3 O2




RN 431043-95-7 CAPLUS
CN 1H-Indole, 1-[(2,4-dichloro-5-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
CH 1
CRN 431043-94-6
CMF C19 H19 Cl2 N3 O2 S



CH 2


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CRN 431044-00-7
CMF C19 H21 N3 O2 S



CH 2
CRN 76-05-1
CMF C2 H F3 O2



RN 431044-03-0 CAPLUS
CN 1H-Indole, 1-[(2,3-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
CH 1
CRN 431044-02-9
CMF C18 H17 Cl2 N3 O2 S



CH 2
CRN 76-05-1
CMF C2 H F3 O2


<06/15/2005>

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 76-05-1
CMF C2 H F3 O2



RN 431043-98-0 CAPLUS
CN 1H-Indole, 1-[(2-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
CH 1
CRN 431043-97-9
CMF C18 H18 Cl N3 O2 S



CH 2
CRN 76-05-1
CMF C2 H F3 O2




RN 431044-01-8 CAPLUS
CN 1H-Indole, 1-[(3-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
CH 1

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431044-04-1 CAPLUS
CN 1H-Indole, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
CH 1
CRN 423175-41-1
CMF C16 H15 Cl2 N3 O2 S2




CH 2
CRN 76-05-1
CMF C2 H F3 O2



RN 431044-06-3 CAPLUS
CN 1H-Indole, 1-[(3-bromo-5-chloro-2-thienyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
CH 1
CRN 431044-05-2
CMF C16 H15 Br Cl N3 O2 S2

Habte

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CH 2

CRN 76-05-1
CMF C2 H F3 O2

RN 431044-09-5 CAPLUS
CN 1H-Indole, 4-((1-piperazinyl)-1-[[5-(2-pyridinyl)-2-thienyl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 431044-07-4
CMF C21 H20 N4 O2 S2

CH 2

CRN 76-05-1

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CH 2

CRN 76-05-1
CMF C2 H F3 O2

RN 431044-13-2 CAPLUS
CN 1H-Indole, 1-[[4-butoxyphenyl)sulfonyl]-4-((1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-12-1
CMF C22 H27 N3 O3 S

CH 2


CRN 76-05-1
CMF C2 H F3 O2

<06/15/2005>

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CMF C2 H F3 O2

RN 431044-09-6 CAPLUS
CN 1H-Indole, 1-[(4-cyanophenyl)sulfonyl]-4-((1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 412048-96-5
CMF C19 H18 N4 O2 S

CH 2

CRN 76-05-1
CMF C2 H F3 O2

RN 431044-11-0 CAPLUS
CN 1H-Indole, 1-[(2-cyanophenyl)sulfonyl]-4-((1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1


CRN 431044-10-9
CMF C19 H18 N4 O2 S

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431044-15-4 CAPLUS
CN 1H-Indole, 1-[(3,6-dibromo-2,5-difluorophenyl)sulfonyl]-4-((1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-14-3
CMF C18 H15 Br2 F2 N3 O2 S

CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 431044-17-6 CAPLUS
CN 1H-Indole, 1-[(3-chloro-1,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-((1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-16-5
CMF C17 H20 Cl N5 O2 S

Habte

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 431044-19-8 CAPLUS
CN 1H-Indole, 1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-18-7
CMF C17 H20 N4 O3 S

CH 2

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


CRN 431044-22-3
CMF C19 H20 F N3 O2 S

CH 2

CRN 76-05-1
CMF C2 H F3 O2

RN 431044-25-6 CAPLUS
CN 1H-Indole, 1-[(5-chloro-2-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-24-5
CMF C19 H20 Cl N3 O3 S

CH 2

CRN 76-05-1
CMF C2 H F3 O2


<06/15/2005>

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 76-05-1
CMF C2 H F3 O2

RN 431044-21-2 CAPLUS
CN 1H-Indole, 1-[[2,5-bis(2,2,2-trifluoroethoxy)phenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-20-1
CMF C22 H21 F6 N3 O4 S

CH 2

CRN 76-05-1
CMF C2 H F3 O2

RN 431044-23-4 CAPLUS
CN 1H-Indole, 1-[(5-fluoro-2-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431044-27-8 CAPLUS
CN 1H-Indole, 1-[(2,5-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-26-7
CMF C18 H17 F2 N3 O2 S

CH 2

CRN 76-05-1
CMF C2 H F3 O2


RN 431044-29-0 CAPLUS
CN 1H-Indole, 1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-28-9
CMF C18 H17 N5 O2 S2

Habte

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CH 2

CRN 76-05-1
CMF C2 H F3 O2RN 431044-30-3 CAPLUS
CN 1H-Indole, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 412049-05-9
CMF C16 H19 N5 O2 S


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2RN 431044-34-7 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 431044-33-6
CMF C18 H19 N3 O4 S2

CH 2

<06/15/2005>

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CH 2

CRN 76-05-1
CMF C2 H F3 O2RN 431044-32-5 CAPLUS
CN 1H-Indole, 1-(2,1,3-benzoxadiazol-4-ylsulfonyl)-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-31-4
CMF C18 H17 N5 O3 S


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 76-05-1

CMF C2 H F3 O2

RN 431044-36-9 CAPLUS
CN 1H-Indole, 1-[[5-(3-isoxazolyl)-2-thienyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-35-8
CMF C19 H18 N4 O3 S2

CH 2


CRN 76-05-1
CMF C2 H F3 O2RN 431044-38-1 CAPLUS
CN 1H-Indole, 1-[(1,1'-biphenyl)-4-ylsulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-37-0
CMF C24 H23 N3 O2 S

Habe


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 431044-39-2 CAPLUS
CN 1H-Indole, 1-[(5-bromo-2-thienyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 423175-40-0
CMF C16 H16 Br N3 O2 S2

CM 2

CRN 76-05-1


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 431044-45-0 CAPLUS
CN 1H-Indole, 1-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-44-9
CMF C19 H17 Br F3 N3 O3 S


CM 2

CRN 76-05-1
CMF C2 H F3 O2

<06/15/2005>

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CMF C2 H F3 O2RN 431044-41-6 CAPLUS
CN 1H-Indole, 1-[(3,4-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-40-5
CMF C18 H17 F2 N3 O2 S

CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 431044-43-8 CAPLUS
CN 1H-Indole, 1-[(4-butylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431044-42-7
CMF C22 H27 N3 O2 S

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 431044-47-2 CAPLUS
CN 1H-Indole, 1-[(5-chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-46-1
CMF C18 H16 Cl N5 O3 S

CM 2


CRN 76-05-1
CMF C2 H F3 O2RN 431044-49-4 CAPLUS
CN 1H-Indole, 1-[(4-bromo-2-ethylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431044-48-3
CMF C20 H22 Br N3 O2 S

Habte

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CH 2

CRN 76-05-1
CHF C2 H F3 O2RN 431044-50-7 CAPLUS
CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)RN 431044-51-8 CAPLUS
CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1


CRN 431044-50-7
CHF C17 H16 Cl N5 O2 S2

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CH 2

CRN 76-05-1
CHF C2 H F3 O2RN 431044-55-2 CAPLUS
CN 1H-Indole, 1-[(2,6-dichloro-4-(trifluoromethyl)phenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-54-1
CHF C19 H16 Cl2 F3 N3 O2 S


CH 2

CRN 76-05-1
CHF C2 H F3 O2RN 431044-57-4 CAPLUS
CN 1H-Indole, 1-(5-isoquinoliny)sulfonyl)-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-56-3
CHF C21 H20 N4 O2 S


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CH 2

CRN 76-05-1
CHF C2 H F3 O2RN 431044-53-0 CAPLUS
CN 1H-Indole, 1-[(4-bromo-2-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-52-9
CHF C19 H20 Br N3 O2 S


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CH 2

CRN 76-05-1
CHF C2 H F3 O2RN 431044-59-6 CAPLUS
CN 1H-Indole, 1-[(4-acetylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-58-5
CHF C20 H21 N3 O3 S

CH 2

Habte

<06/15/2005>


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CRN 76-05-1
 CMF C2 H F3 O2



RN 431044-61-0 CAPLUS
 CN 1H-Indole, 1-[(2-iodophenyl)sulfonyl]-4-(1-piperazinyl)-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-60-9
 CMF C18 H18 I N3 O2 S



CH 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 431044-63-2 CAPLUS
 CN 1H-Indole, 1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-(1-piperazinyl)-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-62-1

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CH 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 431044-67-6 CAPLUS
 CN 1H-Indole, 1-[(2,6-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-66-5
 CMF C18 H17 F2 N3 O2 S



CH 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 431044-69-8 CAPLUS
 CN 1H-Indole, 4-(1-piperazinyl)-1-[(2-(trifluoromethoxy)phenyl)sulfonyl]-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-68-7
 CMF C19 H18 F3 N3 O3 S

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CMF C17 H21 N5 O2 S



CH 2


CRN 76-05-1
 CMF C2 H F3 O2




RN 431044-65-4 CAPLUS
 CN 1H-Indole, 1-[(3-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-64-3
 CMF C19 H21 N3 O3 S



L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CH 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 431044-71-2 CAPLUS
 CN 1H-Indole, 1-[(2-nitrophenyl)sulfonyl]-4-(1-piperazinyl)-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-70-1
 CMF C18 H18 N4 O4 S



CH 2

CRN 76-05-1
 CMF C2 H F3 O2

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STM (Continued)




RN 431044-72-3 CAPLUS
 CH 1H-Indole, 4-[(1-piperazinyl)-1-[[4-(trifluoromethoxy)phenyl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 412049-03-7

CMF C19 H18 F3 N3 O3 S



CH 2

CRN 76-05-1

CMF C2 H F3 O2



RN 431044-74-5 CAPLUS
 CH 1H-Indole, 1-[(2,4-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-73-4

CMF C18 H17 F2 N3 O2 S

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STM (Continued)

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-78-9 CAPLUS
 CH 1H-Indole, 1-[(5-chloro-2-methylbenzo[b]thien-3-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-77-8

CMF C21 H20 Cl N3 O2 S2



CH 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-80-3 CAPLUS
 CH 1H-Indole, 1-[(5-chloro-3-methyl-2-benzofuranyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

<06/15/2005>

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STM (Continued)



CH 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-76-7 CAPLUS
 CH 1H-Indole, 1-[(5,7-dichloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-75-6

CMF C21 H19 Cl2 N3 O2 S2




CH 2

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STM (Continued)

CRN 431044-79-0

CMF C21 H20 Cl N3 O3 S



CH 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-82-5 CAPLUS
 CH 1H-Indole, 1-[(2-chloro-6-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-81-4

CMF C19 H20 Cl N3 O2 S



CH 2

Habe


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CRN 76-05-1
 CMF C2 H F3 O2



RN 431044-84-7 CAPLUS
 CN 1H-Indole, 1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-83-6
 CMF C20 H17 F6 N3 O2 S



CH 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 431044-86-9 CAPLUS
 CN 1H-Indole, 1-[(2,6-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-85-8

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CH 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 431044-89-2 CAPLUS
 CN 1H-Indole, 1-[(3-chloro-5-fluoro-2-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CH 1

CRN 431044-88-1
 CMF C19 H19 Cl F N3 O2 S



<06/15/2005>

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CMF C18 H17 Cl2 N3 O2 S



CH 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 431044-87-0 CAPLUS
 CN 1H-Indole, 1-[(7-chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 412048-97-6
 CMF C18 H16 Cl N5 O3 S

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CH 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 431044-91-6 CAPLUS
 CN 1H-Indole, 1-[(5-(dimethylamino)-1-naphthalenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-90-5
 CMF C24 H26 N4 O2 S



CH 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 431044-93-8 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 431044-92-7

Habte

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CNF C18 H17 C12 N3 O2 S




CH 2
 CRN 76-05-1
 CNF C2 H F3 O2




RN 431044-95-0 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(3,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
 CRN 431044-94-9
 CNF C18 H16 C13 N3 O2 S



CH 2

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CRN 431044-98-3
 CNF C22 H20 C1 N3 O2 S




CH 2
 CRN 76-05-1
 CNF C2 H F3 O2



RN 431045-01-1 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(3,5-dichloro-2-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
 CRN 431045-00-0
 CNF C19 H18 C13 N3 O3 S



CH 2

<06/15/2005>


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CRN 76-05-1
 CNF C2 H F3 O2



RN 431044-97-2 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(2,6-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1
 CRN 431044-96-1
 CNF C18 H16 C13 N3 O2 S



CH 2
 CRN 76-05-1
 CNF C2 H F3 O2




RN 431044-99-4 CAPLUS
 CN 1H-Indole, 5-chloro-1-(2-naphthalenylsulfonyl)-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CRN 76-05-1
 CNF C2 H F3 O2



RN 431045-03-3 CAPLUS
 CN 1H-Indole, 5-methoxy-1-[(4-methylphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-29-3 CAPLUS
 CN 1H-Indole, 1-[(5-chloro-2-naphthalenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-30-6 CAPLUS
 CN 1H-Indole, 1-[(3-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)

Habte


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-31-7 CAPLUS
CN 1H-Indole, 1-[(2,5-dichloro-3-thienyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-32-8 CAPLUS
CN 1H-Indole, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-33-9 CAPLUS
CN 1H-Indole, 1-[(5-chloro-1-naphthalenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-38-4 CAPLUS
CN 1H-Indole, 1-[(4-(1-piperazinyl)-1-[(2-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 431045-39-5 CAPLUS
CN 1H-Indole, 1-[(4-(1-piperazinyl)-1-[(1,1-dimethylethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 431045-40-8 CAPLUS
CN 1H-Indole, 1-[(3-nitrophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-35-1 CAPLUS
CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-36-2 CAPLUS
CN 1H-Indole, 1-[(3-chloro-4-methylphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-37-3 CAPLUS
CN 1H-Indole, 1-[(1-naphthalenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-41-9 CAPLUS
CN 1H-Indole, 1-[(2-thienyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-42-0 CAPLUS
CN 1H-Indole, 1-[(3,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-43-1 CAPLUS
CN 1H-Indole, 1-[(3-chloro-4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-44-2 CAPLUS
CN 1H-Indole, 1-(2-dibenzofuranylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-45-3 CAPLUS
CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-46-4 CAPLUS
CN 1H-Indole, 1-[(3-chloro-2-methylphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-50-0 CAPLUS
CN 1H-Indole, 1-[(2-chloro-3,5-difluorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-51-1 CAPLUS
CN 1H-Indole, 5-chloro-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

<06/15/2005>


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431045-47-5 CAPLUS
CN 1H-Indole, 1-(2-naphthalenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-48-6 CAPLUS
CN 1H-Indole, 1-[(3,5-dichloro-2-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 431045-49-7 CAPLUS
CN 1H-Indole, 4-[(1-piperazinyl)-1-[(2,3,5-trichlorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 431045-52-2 CAPLUS
CN 1H-Indole, 4-[(1-piperazinyl)-1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-53-3 CAPLUS
CN 1H-Indole, 1-[(4-bromo-2-(trifluoromethoxy)phenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-54-4 CAPLUS
CN 1H-Indole, 5-chloro-1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-55-5 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(2,6-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-56-6 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(2-bromophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-57-7 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(2-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-58-8 CAPLUS
 CN 1H-Indole, 5-chloro-4-(1-piperazinyl)-1-[(3-(trifluoromethyl)phenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-59-9 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(3-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-60-2 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(3-bromophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-61-3 CAPLUS
 CN 1H-Indole, 1-[(4-bromo-2-(trifluoromethoxy)phenyl)sulfonyl]-5-chloro-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-62-4 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(3-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-63-5 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(1-naphthalenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-64-6 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(2,5-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-65-7 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-66-8 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-67-9 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-68-0 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(1-piperazinyl)-1-(2-pyridinyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-69-1 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(2,5-dimethylphenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-70-4 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-71-5 CAPLUS
 CN 1H-Indole, 7-chloro-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-72-6 CAPLUS
 CN 1H-Indole, 7-chloro-1-[(3,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-73-7 CAPLUS
 CN 1H-Indole, 7-chloro-1-[(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-74-8 CAPLUS
 CN 1H-Indole, 1-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-7-chloro-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-75-9 CAPLUS
 CN 1H-Indole, 7-bromo-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-76-0 CAPLUS
 CN 1H-Indole, 7-carbonitrile, 1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-77-1 CAPLUS
 CN 1H-Indole, 3,5-dichloro-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-78-2 CAPLUS
 CN 1H-Indole, 5,7-dichloro-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 431045-80-6 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(3-chlorophenyl)sulfonyl]-4-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 431045-81-7 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(3-chlorophenyl)sulfonyl]-4-[(3S)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-84-0 CAPLUS
 CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-85-1 CAPLUS
 CN 1H-Indole, 6-chloro-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 431045-82-8 CAPLUS
 CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-5-fluoro-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-83-9 CAPLUS
 CN 1H-Indole-5-carbonitrile, 1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-86-2 CAPLUS
 CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-3-methyl-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-87-3 CAPLUS
 CN 1H-Indole, 1-[(4-chloro-2-(trifluoromethoxy)phenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-88-4 CAPLUS
 CN 1H-Indole, 5-chloro-1-[(4-chloro-2-(trifluoromethoxy)phenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-89-5 CAPLUS
 CN 1H-Indole, 1-[(4-bromo-2-cyanophenyl)sulfonyl]-5-chloro-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-90-8 CAPLUS
 CN 1H-Indole, 1-[(4-bromo-2-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-91-9 CAPLUS
 CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-5-methoxy-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 431045-92-0 CAPLUS
 CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-7-methoxy-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 431045-95-3P 431045-97-5P 431046-01-4P
 431046-04-7P 431046-05-8P 431046-07-0P
 431046-08-1P 431046-13-8P 431046-14-9P
 431046-18-3P 431046-23-0P 431046-24-1P
 431046-34-3P 431046-35-4P
 RL: RCT (Reactant); SFN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Preparation of 4-piperazinoindoles for treating CNS disorders)
 RN 431045-95-3 CAPLUS
 CN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-4-(4-phenylmethyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 431045-97-5 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[5-chloro-1-[(3-chlorophenyl)sulfonyl]-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 431046-01-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[1-[(3-chlorophenyl)sulfonyl]-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 431046-04-7 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[3-chloro-1-[(3-chlorophenyl)sulfonyl]-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 431046-05-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[7-chloro-1-[(3-chlorophenyl)sulfonyl]-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 431046-07-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[7-bromo-1-[(3-chlorophenyl)sulfonyl]-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 431046-08-1 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[1-[(3-chlorophenyl)sulfonyl]-7-cyano-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 431046-13-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[1-[(3-chlorophenyl)sulfonyl]-5-cyano-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431046-14-9 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[1-[(3-chlorophenyl)sulfonyl]-2-methyl-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 431046-18-3 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[1-[(3-chlorophenyl)sulfonyl]-3-methoxy-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 431046-23-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[1-[(3-chlorophenyl)sulfonyl]-5-methoxy-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 431046-24-1 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[1-[(3-chlorophenyl)sulfonyl]-7-methoxy-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 431046-34-3 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[1-[(3-chlorophenyl)sulfonyl]-3-methyl-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

own work

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 431046-35-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

2002:353426 CAPLUS
DOCUMENT NUMBER: 136:369738
TITLE: Preparation of 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
INVENTOR(S): Kelly, Michael Gerard; Cole, Derek Cecil
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036562	A2	20020510	WO 2001-US45389	20011031
WO 2002036562	A3	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, HR, NE, SN, TD, TG				
CA 2426031	AA	20020510	CA 2001-2426031	20011031
AU 2002020051	A5	20020515	AU 2002-20051	20011031
EP 1343756	A2	20030917	EP 2001-992697	20011031
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015102	A	20030930	BR 2001-15102	20011031
JP 2004513111	T2	20040430	JP 2002-539322	20011031
NZ 525592	A	20040730	NZ 2001-525592	20011031
NO 2003001977	A	20030630	NO 2003-1977	20030430
ZA 2003004188	A	20040830	ZA 2003-4188	20030529
PRIORITY APPL. INFO.:			US 2000-245118P	P 20001102
			WO 2001-0545389	W 20011031


OTHER SOURCE(S): MARPAT 136:369738
GI




L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB The title compds. [I; A = C, CR10, N; X = CR11, N; Y = CR7, N with the proviso that when X = N, then Y must be CR7; R1 = H, alkylcarbonyl, alkoxy, etc.; R2-R6 = H, halo, OH, alkyl; R7, R11 = H, halo, alkyl, etc.; R8 = alkyl, aryl, heteroaryl; R9 = H, halo, alkyl, etc.; R10 = H, OH, alkoxy; m = 1-3; n = 0-3] and their salts, useful in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor, were prepared. Thus, protecting 1H-indole-4-ylpiperazine with di-tert-Bu dicarbonate followed by reacting the resulting tert-Bu 4-(1H-indol-4-yl)piperazine-1-carboxylate with benzenesulfonyl chloride (81%), and deprotection (99%) afforded II.HCl which showed Ki of 1.0 nM against 5-HT6 binding.

IT 412049-71-9P 423174-78-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands)
RN 412049-71-9 CAPLUS
CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 423174-78-1 CAPLUS
CN 1H-Indazole, 4-[4-(phenylmethyl)-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




IT 393508-47-9P 412048-59-0P 412048-92-1P

<06/15/2005>

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

412049-03-7P 423174-01-0P 423174-03-2P
423174-05-4P 423174-09-8P 423174-10-1P
423174-11-2P 423174-13-4P 423174-15-6P
423174-17-8P 423174-19-0P 423174-21-4P
423174-23-6P 423174-25-8P 423174-27-0P
423174-29-2P 423174-31-6P 423174-33-8P
423174-35-0P 423174-37-2P 423174-39-4P
423174-41-8P 423174-43-0P 423174-45-2P
423174-47-4P 423174-48-5P 423174-50-9P
423174-52-1P 423174-54-3P 423174-56-5P
423174-57-6P 423174-58-7P 423174-59-8P
423174-61-2P 423174-63-4P 423174-65-6P
423174-66-7P 423174-67-8P 423174-68-9P
423174-69-0P 423174-71-4P 423174-72-5P
423174-73-6P 423174-74-7P 423174-76-9P
423174-79-2P 423174-81-6P 423174-82-7P
423174-84-9P 423174-85-0P 423174-87-2P
423174-89-4P 423174-90-7P 423174-91-8P
423174-93-0P 423174-94-1P 423174-95-2P
423174-96-3P 423174-97-4P 423174-98-5P
423175-00-2P 423175-01-3P 423175-02-4P
423175-03-5P 423175-04-6P 423175-05-7P
423175-06-8P 423175-07-9P 423175-08-0P
423175-10-4P 423175-12-5P 423175-14-8P
423175-16-0P 423175-18-2P 423175-20-6P
423175-22-8P 423175-24-0P 423175-26-2P
423175-27-3P 423175-28-4P 423175-29-5P
423175-30-8P 423175-31-9P 423175-32-0P
423175-33-1P 423175-34-2P 423175-35-3P
423175-36-4P 423175-37-5P 423175-38-6P
423175-40-0P 423175-41-1P 423175-42-2P
423175-43-3P 423175-44-4P 423175-45-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands)
RN 393508-47-9 CAPLUS
CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

Habte


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 412048-59-0 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412048-92-1 CAPLUS
 CN 1H-Indole, 1-[(4-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412049-03-7 CAPLUS
 CN 1H-Indole, 4-[(1-piperazinyl)-1-[(4-(trifluoromethoxy)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)]

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-01-0 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 423174-03-2 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 423174-05-4 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-(1-piperazinyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 423174-09-8 CAPLUS
 CN 1H-Indole, 4-[(4-(4,5-dihydro-1H-imidazol-2-yl)-1-piperazinyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)]

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-10-1 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[(4,5-dihydro-1H-imidazol-2-yl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-11-2 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[(4,5-dihydro-1H-imidazol-2-yl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-13-4 CAPLUS
 CN 1H-Indole, 4-[(4-(4,5-dihydro-1H-imidazol-2-yl)-1-piperazinyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 423174-15-6 CAPLUS
 CN 1H-Indole, 4-[(4-aminophenyl)sulfonyl]-4-[4-(4,5-dihydro-1H-imidazol-2-yl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-21-4 CAPLUS
 CN 1H-Indole, 4-[(3-nitrophenyl)methyl]-1-piperazinyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 423174-23-6 CAPLUS
 CN Piperazine, 1-acetyl-4-[1-(phenylsulfonyl)-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-17-8 CAPLUS
 CN 1H-Indole, 4-[(4-(phenylmethyl)-1-piperazinyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 423174-19-0 CAPLUS
 CN 1H-Indole, 4-[(5-chloro-2-thienyl)methyl]-1-piperazinyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-25-8 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-27-0 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[4-(5-chloro-2-thienyl)methyl]-1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-29-2 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[(3-nitrophenyl)methyl]-1-piperazinyl- (9CI) (CA INDEX NAME)




RN 423174-31-6 CAPLUS
 CN Piperazine, 1-acetyl-4-[1-[(2-bromophenyl)sulfonyl]-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-37-2 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[(3-nitrophenyl)methyl]-1-piperazinyl- (9CI) (CA INDEX NAME)




RN 423174-39-4 CAPLUS
 CN Piperazine, 1-acetyl-4-[1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-1H-indol-4-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-33-8 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-35-0 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[(5-chloro-2-thienyl)methyl]-1-piperazinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-41-8 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-[(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-43-0 CAPLUS
 CN 1H-Indole, 4-[(3,4-dimethoxyphenyl)sulfonyl]-1-[(3,4-dimethoxyphenyl)sulfonyl]-1-piperazinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-45-2 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-[(3-nitrophenyl)methyl]-1-piperazinyl- (9CI) (CA INDEX NAME)




RN 423174-47-4 CAPLUS
 CN Piperazine, 1-acetyl-4-[(3,4-dimethoxyphenyl)sulfonyl]-1H-indol-4-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 423174-48-5 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-50-9 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423174-52-1 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(5-chloro-2-thienyl)methyl]-1- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-54-3 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(3-nitrophenyl)methyl]-1-piperazinyl- (9CI) (CA INDEX NAME)




RN 423174-56-5 CAPLUS
 CN 1H-Indole, 4-[(4-[(3-methoxyphenyl)methyl]-1-piperazinyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-57-6 CAPLUS
 CN 1H-Indole, 1-(phenylsulfonyl)-4-[(4-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-58-7 CAPLUS
 CN 1H-Indole, 1-(phenylsulfonyl)-4-[(3-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-59-8 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[(3-methoxyphenyl)methyl]-1-piperazinyl- (9CI) (CA INDEX NAME)




RN 423174-61-2 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[(4-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-66-7 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[(4-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-67-8 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[(3-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-63-4 CAPLUS
 CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[(3-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-65-6 CAPLUS
 CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[(3-methoxyphenyl)methyl]-1-piperazinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-68-9 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-[(3-methoxyphenyl)methyl]-1-piperazinyl- (9CI) (CA INDEX NAME)




RN 423174-69-0 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-[(4-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-71-4 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-[(3-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-72-5 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(3-methoxyphenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-73-6 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(4-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-74-7 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[(3-pyridinylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-76-9 CAPLUS
 CN 1H-Indazole, 4-[(4-aminophenyl)sulfonyl]-1-[(phenylmethyl)-1-piperazinyl]- (phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 423174-79-2 CAPLUS
 CN 1H-Indazole, 1-[(phenylsulfonyl)-1-piperazinyl]-4-[(1-piperazinyl)-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 423174-81-6 CAPLUS
 CN 1H-Indazole, 4-[(2-phenylethyl)-1-piperazinyl]-1-[(phenylsulfonyl)-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 423174-82-7 CAPLUS
 CN 1H-Indazole, 4-[(2-phenylethyl)-1-piperazinyl]-1-[(phenylsulfonyl)-1-piperazinyl]- (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-84-9 CAPLUS
 CN 1H-Indazole, 4-[4-(2-(4-fluorophenoxy)ethyl)-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 423174-89-4 CAPLUS
 CN 1H-Indazole, 4-[4-(3-phenylpropyl)-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 423174-90-7 CAPLUS
 CN 1H-Indazole, 1-(phenylsulfonyl)-4-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 423174-85-0 CAPLUS
 CN 1H-Indazole, 4-[4-(4-(4-fluorophenyl)-4-oxobutyl)-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 423174-87-2 CAPLUS
 CN 1H-Indazole, 4-[4-(2-oxo-2-phenylethyl)-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 423174-91-8 CAPLUS
 CN 1H-Indazole, 1-[(2-phenylethenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-93-0 CAPLUS
 CN 1H-Indazole, 1-[(4-fluorophenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-94-1 CAPLUS

Habe

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 1H-Indazole, 1-[(4-chlorophenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-95-2 CAPLUS
 CN 1H-Indazole, 1-[(4-methoxyphenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-96-3 CAPLUS
 CN 1H-Indazole, 4-[4-(phenylmethyl)-1-piperazinyl]-1-[[4-(trifluoromethoxy)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423174-97-4 CAPLUS
 CN 1H-Indazole, 1-[(4,6-dichloro-2-thienyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-98-5 CAPLUS
 CN 1H-Indazole, 1-[(4-methylphenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423175-00-2 CAPLUS
 CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-5-[1-piperazinyl]-, hydrochloride (9CI) (CA INDEX NAME)




• x HCl

RN 423175-01-3 CAPLUS
 CN 1H-Benzimidazole, 1-(phenylsulfonyl)-5-[1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423175-02-4 CAPLUS
 CN 1H-Benzimidazole, 1-(phenylsulfonyl)-6-[1-piperazinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423175-03-5 CAPLUS
 CN 1H-Indole, 1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-5-[1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 423175-04-6 CAPLUS
 CN 1H-Benzimidazole, 1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-6-[1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423175-05-7 CAPLUS
 CN 1H-Benzimidazole, 1-[(2-bromophenyl)sulfonyl]-6-[1-piperazinyl]- (9CI) (CA INDEX NAME)




<06/15/2005>

Habte


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 423175-06-8 CAPLUS
 CN 1H-Benzimidazole, 1-[(2-bromophenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-07-9 CAPLUS
 CN 1H-Benzimidazole, 1-[(4-bromophenyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 423175-08-0 CAPLUS
 CN 1H-Benzimidazole, 1-[(5-bromo-2-thienyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-10-4 CAPLUS
 CN 1H-Benzimidazole, 1-[(5-bromo-2-thienyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-12-6 CAPLUS
 CN 1H-Indole, 1-[(4-butoxyphenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423175-14-8 CAPLUS
 CN 1H-Benzimidazole, 1-[(4-butoxyphenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 423175-16-0 CAPLUS
 CN 1H-Benzimidazole, 1-[(4-butoxyphenyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-18-2 CAPLUS
 CN 1H-Indole, 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-20-6 CAPLUS
 CN 1H-Benzimidazole, 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423175-22-8 CAPLUS
 CN 1H-Benzimidazole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 423175-24-0 CAPLUS
 CN 1H-Benzimidazole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-26-2 CAPLUS
 CN 1H-Benzimidazole, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-27-3 CAPLUS
 CN 1H-Benzimidazole, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423175-28-4 CAPLUS
 CN 1H-Benzimidazole, 1-[(4-fluorophenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-29-5 CAPLUS
 CN 1H-Benzimidazole, 1-[(4-fluorophenyl)sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 423175-30-8 CAPLUS
 CN 1H-Benzimidazole, 1-[(4-methoxyphenyl)sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-31-9 CAPLUS
 CN 1H-Indole, 1-(2-naphthalenylsulfonyl)-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)




<06/15/2005>

Habte


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 423175-32-0 CAPLUS
 CN 1H-Benzimidazole, 1-(2-naphthalenylsulfonyl)-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-33-1 CAPLUS
 CN 1H-Indole, 5-(1-piperazinyl)-1-[[4-(trifluoromethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 423175-34-2 CAPLUS
 CN 1H-Benzimidazole, 5-(1-piperazinyl)-1-[[4-(trifluoromethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 423175-35-3 CAPLUS
 CN 1H-Benzimidazole, 6-(1-piperazinyl)-1-[[4-(trifluoromethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 423175-36-4 CAPLUS
 CN 1H-Indole, 1-[[4-iodophenyl]sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 423175-37-5 CAPLUS
 CN 1H-Benzimidazole, 1-[[4-iodophenyl]sulfonyl]-5-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 423175-38-6 CAPLUS
 CN 1H-Indole, 1-[[4-iodophenyl]sulfonyl]-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-40-0 CAPLUS
 CN 1H-Indole, 1-[[5-bromo-2-thienyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-41-1 CAPLUS
 CN 1H-Indole, 1-[[4,5-dichloro-2-thienyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 423175-42-2 CAPLUS
 CN 1H-Indole, 1-[[4-methoxyphenyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)





RN 423175-43-3 CAPLUS
 CN 1H-Indazole, 1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423722-47-8 CAPLUS
 CN 1H-Indazole, 1-(naphthalenylsulfonyl)-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 423175-39-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands)


RN 423175-39-7 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[1-[[4-(acetamino)phenyl]sulfonyl]-1H-indol-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 393508-48-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands)

RN 393508-48-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[1-(phenylsulfonyl)-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:314905 CAPLUS
 DOCUMENT NUMBER: 136:309847
 TITLE: 2-, 3-, 4-, or 5-substituted-1-(benzenesulfonyl)indoles and their use in therapy
 INVENTOR(S): Caldirola, Patrizia; Johansson, Gary; Nilsson, Björn M.
 PATENT ASSIGNEE(S): Biocitum AB, Swed.
 SOURCE: PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032863	A1	20020425	WO 2001-5E2319	20011019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LX, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422717	AA	20020425	CA 2001-2422717	20011019
AU 2001096193	A5	20020429	AU 2001-96193	20011019
BR 2001014552	A	20030701	BR 2001-14552	20011019
EP 1326830	A1	20030716	EP 2001-977043	20011019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001693	A	20040301	ZA 2003-1693	20011019
JP 2004524276	T2	20040812	JP 2002-536047	20011019
NZ 524675	A	20040924	NZ 2001-524675	20011019
US 2002165251	A1	20021107	US 2001-37110	20011022
NO 2003001589	A	20030528	NO 2003-1589	20030408
PRIORITY APPLN. INFO.:			SE 2000-3810	A 20001020
			US 2000-243115P	P 20001025
			WO 2001-5E2319	W 20011019

OTHER SOURCE(S): MARPAT 136:309847
 AB Approx. 130 title compds. and their HCl salts were prepared by standard methods.


The said compds. have affinity for the 5-HT₂ receptor and are useful for the treatment and prophylaxis of disorders relating to the said receptor, such as obesity and CNS disorders.

IT 393508-48-0 412049-80-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of antiobesity benzenesulfonylindoles)
 RN 393508-48-0 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[1-(phenylsulfonyl)-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 412049-80-0 CAPLUS
 CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-5-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




IT 412049-09-3P 412049-39-9P 412049-41-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of antiobesity benzenesulfonylindoles)
 RN 412049-09-3 CAPLUS
 CN 1H-Indole, 5-(4-methyl-1-piperazinyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 412049-39-9 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-iodo-1-(phenylsulfonyl)-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 412049-41-3 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-phenyl-1-(phenylsulfonyl)-1H-indol-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 393508-47-9P 412048-49-8P 412048-50-1P
 412048-51-2P 412048-52-3P 412048-53-4P
 412048-54-5P 412048-55-6P 412048-56-7P
 412048-57-8P 412048-58-9P 412048-59-0P
 412048-61-4P 412048-63-6P 412048-64-7P
 412048-65-8P 412048-66-9P 412048-67-0P
 412048-68-1P 412048-69-2P 412048-70-5P
 412048-71-6P 412048-72-7P 412048-73-8P
 412048-75-0P 412048-76-1P 412048-79-4P
 412048-80-7P 412048-81-8P 412048-84-1P
 412048-85-2P 412048-86-3P 412048-89-6P
 412048-90-9P 412048-91-0P 412048-92-1P
 412048-93-2P 412048-94-3P 412048-95-4P
 412048-96-5P 412048-97-6P 412048-98-7P
 412048-99-8P 412049-00-9P 412049-01-5P
 412049-02-6P 412049-03-7P 412049-04-8P
 412049-05-9P 412049-10-6P 412049-11-7P

Habte

<06/15/2005>

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


412049-12-8P 412049-13-8P 412049-14-0P
 412049-15-1P 412049-16-2P 412049-17-3P
 412049-18-4P 412049-19-5P 412049-20-6P
 412049-21-9P 412049-22-0P 412049-23-1P
 412049-24-2P 412049-25-3P 412049-26-4P
 412049-27-5P 412049-28-6P 412049-29-7P
 412049-30-0P 412049-31-1P 412049-32-2P
 412049-33-3P 412049-34-4P 412049-35-5P
 412049-36-6P 412049-37-7P 412049-40-2P
 412049-42-4P 412049-45-7P 412049-49-1P
 412049-50-4P 412049-51-5P 412049-54-8P
 412049-55-9P 412049-56-0P 412049-59-3P
 412049-60-6P 412049-61-7P 412049-62-8P
 412049-63-9P 412049-64-0P 412049-65-1P
 412049-66-2P 412049-67-3P 412049-68-4P
 412049-69-5P 412049-70-6P 412049-71-9P
 412049-72-0P 412049-73-1P 412049-74-2P
 412049-75-3P 412049-76-4P
 RL: SPN (Synthetic preparation), PREP (Preparation)
 (prepn. of anticobesity benzenesulfonylindoles)
 RN 393508-47-9 CAPLUS
 CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl


RN 412048-49-8 CAPLUS
 CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, dihydrochloride (9CI)
 (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● 2 HCl


RN 412048-50-1 CAPLUS
 CN 1H-Indole, 1-[(2,5-dimethoxyphenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-51-2 CAPLUS
 CN 1H-Indole, 4-(1-piperazinyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]-,
 monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412048-52-3 CAPLUS
 CN 1H-Indole, 1-[(1-naphthalenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-53-4 CAPLUS
 CN 1H-Indole, 1-[(5-(dimethylamino)-1-naphthalenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412048-54-5 CAPLUS
 CN 1H-Indole, 4-(1-piperazinyl)-1-[(4-propoxyphenyl)sulfonyl]-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-55-6 CAPLUS
 CN 1H-Indole, 1-[(2,5-dichloro-3-thienyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412048-56-7 CAPLUS
 CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-57-8 CAPLUS
 CN 1H-Indole, 1-[(2,4-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412048-58-9 CAPLUS
 CN 1H-Indole, 1-[(1,1'-biphenyl)-4-ylsulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-59-0 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412048-61-4 CAPLUS
 CN 1H-Indole, 1-[(2-methoxy-5-methylphenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-63-6 CAPLUS
 CN 1H-Indole, 1-[(2,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412048-64-7 CAPLUS
 CN 1H-Indole, 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-65-8 CAPLUS
 CN 1H-Indole, 1-[(3-chloro-2-methylphenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412048-66-9 CAPLUS
 CN 1H-Indole, 1-[(4-(4-chloro-3-methoxyphenyl)sulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-67-0 CAPLUS
 CN 1H-Indole, 1-[(5-bromo-2-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412048-68-1 CAPLUS
 CN 1H-Indole, 4-(1-piperazinyl)-1-(3-pyridinylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-69-2 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-7-[(4-(1-piperazinyl)-1H-indol-1-yl)sulfonyl]-2-(trifluoroacetyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412048-70-5 CAPLUS
 CN 1H-Indole, 1-[(2-(methylsulfonyl)phenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-71-6 CAPLUS
 CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412048-72-7 CAPLUS
 CN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-73-8 CAPLUS
 CN 1H-Indole, 1-[(4-methylphenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 412048-75-0 CAPLUS
 CN 1H-Indole, 4-[(4-methylphenyl)sulfonyl]-1-[(4-(trifluoromethyl)phenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 412048-76-1 CAPLUS
 CN 1H-Indole, 4-[(4-methylphenyl)sulfonyl]-1-[(4-(trifluoromethyl)phenyl)sulfonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 412048-81-8 CAPLUS
 CN 1H-Indole, 1-[(2-methylphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412048-84-1 CAPLUS
 CN 1H-Indole, 4-[(2-methylphenyl)sulfonyl]-4-(3-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 412048-85-2 CAPLUS
 CN 1H-Indole, 4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-[(2-methylphenyl)sulfonyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 412048-86-3 CAPLUS


<06/15/2005>

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● 2 HCl

RN 412048-79-4 CAPLUS
 CN 1H-Indole, 1-[(2-methylphenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412048-80-7 CAPLUS
 CN 1H-Indole, 4-[(4-ethyl-1-piperazinyl)-1-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 412048-81-8 CAPLUS
 CN 1H-Indole, 1-[(2-methylphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412048-89-6 CAPLUS
 CN 1H-Indole, 4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-(phenylsulfonyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 412048-90-9 CAPLUS
 CN 1H-Indole, 4-[(4-ethyl-1-piperazinyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




Habte

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 412048-91-0 CAPLUS
 CN 1H-Indole, 1-[(4-nitrophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 412048-92-1 CAPLUS
 CN 1H-Indole, 1-[(4-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412048-93-2 CAPLUS
 CN 1H-Indole, 1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 412048-97-6 CAPLUS
 CN 1H-Indole, 1-[(7-chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 412048-98-7 CAPLUS
 CN 1H-Indole, 1-[(3-cyanophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412048-99-8 CAPLUS
 CN 1H-Indole, 1-[(4-phenoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 412048-94-3 CAPLUS
 CN 1H-Indole, 1-[(1E)-2-phenylethenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 412048-95-4 CAPLUS
 CN 1H-Indole, 4-[(1-piperazinyl)-1-[(3-(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 412048-96-5 CAPLUS
 CN 1H-Indole, 1-[(4-cyanophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 412049-00-4 CAPLUS
 CN 1H-Indole, 1-[(4-chlorophenyl)methylsulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 412049-01-5 CAPLUS
 CN 1H-Indole, 1-[(4-methylphenyl)methylsulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412049-02-6 CAPLUS
 CN 1H-Indole, 1-[(1,1-diphenylethyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




Habe


L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 412049-03-7 CAPLUS
 CN 1H-Indole, 4-[(1-piperazinyl)-1-[[4-(trifluoromethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 412049-04-8 CAPLUS
 CN Benzamide, N-[[5-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 412049-05-9 CAPLUS
 CN 1H-Indole, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 412049-13-9 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-5-(4-propyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-14-0 CAPLUS
 CN 1H-Indole, 1-[(3-fluorophenyl)sulfonyl]-5-(4-propyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-15-1 CAPLUS
 CN 1H-Indole, 5-[4-methyl-1-piperazinyl]-1-[(4-propylphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 412049-10-6 CAPLUS
 CN 1H-Indole, 1-[(4-methylphenyl)sulfonyl]-5-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412049-11-7 CAPLUS
 CN 1H-Indole, 5-[4-(1-methylethyl)-1-piperazinyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 412049-12-8 CAPLUS
 CN 1H-Indole, 5-[4-(1-methylethyl)-1-piperazinyl]-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 412049-16-2 CAPLUS
 CN 1H-Indole, 5-[4-methyl-1-piperazinyl]-1-(1-naphthalenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-17-3 CAPLUS
 CN 1H-Indole, 1-[(1,1'-biphenyl)-4-ylsulfonyl]-5-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-18-4 CAPLUS
 CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-5-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 412049-19-5 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-5-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-20-8 CAPLUS
 CN 1H-Indole, 1-[(2,4-difluorophenyl)sulfonyl]-5-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-21-9 CAPLUS
 CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-5-(4-(phenylmethyl)-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 412049-25-3 CAPLUS
 CN 1H-Indole, 1-[(1,1'-biphenyl)-4-ylsulfonyl]-5-(4-(phenylmethyl)-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-26-4 CAPLUS
 CN 1H-Indole, 1-[(1-naphthalenyl)sulfonyl]-5-(4-(phenylmethyl)-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-27-5 CAPLUS
 CN 1H-Indole, 5-(4-(phenylmethyl)-1-piperazinyl)-1-[(4-propylphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 412049-22-0 CAPLUS
 CN 1H-Indole, 1-[(2,4-difluorophenyl)sulfonyl]-5-(4-(phenylmethyl)-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-23-1 CAPLUS
 CN 1H-Indole, 1-[(4-butoxyphenyl)sulfonyl]-5-(4-(phenylmethyl)-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-24-2 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-5-(4-(phenylmethyl)-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 412049-28-6 CAPLUS
 CN 1H-Indole, 1-[(2-fluorophenyl)sulfonyl]-5-(4-(phenylmethyl)-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-29-7 CAPLUS
 CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-5-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-30-0 CAPLUS
 CN 1H-Indole, 1-[(2,4-difluorophenyl)sulfonyl]-5-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● HCl

RN 412049-31-1 CAPLUS
 CN 1H-Indole, 1-[(4-butoxyphenyl)sulfonyl]-5-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-32-2 CAPLUS
 CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-5-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 412049-33-3 CAPLUS
 CN 1H-Indole, 1-[(1,1'-biphenyl)-4-ylsulfonyl]-5-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● 2 HCl

RN 412049-37-7 CAPLUS
 CN 1H-Indole, 1-(phenylsulfonyl)-5-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 412049-40-2 CAPLUS
 CN 1H-Indole, 2-iodo-1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-42-4 CAPLUS
 CN 1H-Indole, 2-phenyl-1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


<06/15/2005>

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




● 2 HCl

RN 412049-34-4 CAPLUS
 CN 1H-Indole, 1-(2-naphthalenylsulfonyl)-5-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 412049-35-5 CAPLUS
 CN 1H-Indole, 5-(1-piperazinyl)-1-[(4-propylphenyl)sulfonyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 412049-36-6 CAPLUS
 CN 1H-Indole, 1-[(2-fluorophenyl)sulfonyl]-5-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412049-45-7 CAPLUS
 CN 1H-Indole, 2-methyl-1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 412049-49-1 CAPLUS
 CN 1H-Indole, 1-[(2-methylphenyl)sulfonyl]-4-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412049-50-4 CAPLUS
 CN 1H-Indole, 4-[(4-ethyl-1-piperazinyl)-1-[(2-methylphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-51-5 CAPLUS
 CN 1H-Indole, 1-[(2-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 412049-54-8 CAPLUS
 CN 1H-Indole, 1-[(2-methylphenyl)sulfonyl]-4-(3-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-55-9 CAPLUS
 CN 1H-Indole, 4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-[(2-methylphenyl)sulfonyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 412049-56-0 CAPLUS
 CN 1H-Indole, 4-[(1-methylethyl)-1-piperazinyl]-1-[(2-methylphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 412049-59-3 CAPLUS
 CN 1H-Indole, 4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-(phenylsulfonyl)-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412049-60-6 CAPLUS
 CN 1H-Indole, 4-(4-ethyl-1-piperazinyl)-1-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-61-7 CAPLUS
 CN 1H-Indole, 4-(1-piperazinyl)-1-[(3-(trifluoromethyl)phenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412049-62-8 CAPLUS
 CN 1H-Indole, 1-[(4-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-63-9 CAPLUS
 CN 1H-Indole, 1-[(7-chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412049-66-2 CAPLUS
 CN 1H-Indole, 1-[(4-chlorophenyl)methylsulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-67-3 CAPLUS
 CN 1H-Indole, 1-[(4-methylphenyl)methylsulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412049-64-0 CAPLUS
 CN 1H-Indole, 1-[(3-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-65-1 CAPLUS
 CN 1H-Indole, 1-[(4-phenoxyphenyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412049-68-4 CAPLUS
 CN 1H-Indole, 1-[(1,1-diphenylethyl)sulfonyl]-4-(1-piperazinyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-69-5 CAPLUS
 CN 1H-Indole, 4-(1-piperazinyl)-1-[(4-(trifluoromethoxy)phenyl)sulfonyl]-,
 monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 412049-70-8 CAPLUS
CN Benzamide, N-[[5-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-2-thienyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412049-71-9 CAPLUS
CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 412049-74-2 CAPLUS
CN 1H-Indole, 1-[(4-bromophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412049-75-3 CAPLUS
CN 1H-Indole, 1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 412049-76-4 CAPLUS
CN 1H-Indole, 1-[[[1E]-2-phenylethenyl]sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 412049-72-0 CAPLUS
CN 1H-Indole, 1-[(2,5-dimethoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 412049-73-1 CAPLUS
CN 1H-Indole, 1-[(4-nitrophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 2002:89898 CAPLUS
 DOCUMENT NUMBER: 136:12987
 TITLE: New combination of serotonin 5-HT_{2c} agonist and 5-HT₆ antagonist as pharmaceutical formulation, and therapeutic uses
 INVENTOR(S): Jossan, Sukhwinder; Nilsson, Bjorn M.; Sakariassen, Kjell S.; Svartengren, Jan
 PATENT ASSIGNEE(S): Biocitrum AB, Swed.
 SOURCE: PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008178	A1	20020131	WO 2001-SE1651	20010719
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, CN, GN, GW, ML, HR, NE, SN, TD, TG				
CA 2411192	AA	20020131	CA 2001-2411192	20010719
EP 1301476	A1	20030416	EP 2001-961472	20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012661	A	20030624	BR 2001-12661	20010719
JP 2004504376	T2	20040212	JP 2002-514087	20010719
US 2002068732	A1	20020606	US 2001-908801	20010720
US 6818639	B2	20041116		
ZA 2002010234	A	20040318	ZA 2002-10234	20021218
NO 2003000304	A	20030312	NO 2003-304	20030120
PRIORITY APPLN. INFO.:			SE 2000-2754	A 20000721
			US 2000-222283P	P 20000801
			WO 2001-SE1651	W 20010719


AB The invention relates to a method of preventing or treating a disease related to the 5-HT_{2c} receptor and the 5-HT₆ receptor, comprising administering to a human or animal subject in need thereof a 5-HT_{2c} receptor agonist and a 5-HT₆ receptor antagonist in sufficient amounts to provide a therapeutic effect. The invention also relates to a pharmaceutical composition comprising an effective amount of a combination of a 5-HT_{2c} receptor agonist and a 5-HT₆ receptor antagonist, and optionally a pharmaceutically acceptable carrier. The pharmaceutical combination of the invention may be used to treat eating disorders, CNS disorders, urinary incontinence, and glaucoma.

IT 393508-48-0P
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction; serotonin 5-HT_{2c} agonist-5-HT₆ antagonist)

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 ACCESSION NUMBER: 2001:31461 CAPLUS
 DOCUMENT NUMBER: 134:100770
 TITLE: Preparation of indoline or tetrahydroquinoline derivatives as inhibitors of activated blood coagulation factor X
 INVENTOR(S): Fujimoto, Koichi; Asai, Fumitoshi; Tanaka, Naoki; Matsushashi, Hayao; Sugidachi, Atsuhiko; Tanimoto, Tatsu
 PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan
 SOURCE: PCT Int. Appl., 431 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



IT 393508-47-9P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (serotonin 5-HT_{2c} agonist-5-HT₆ antagonist combination pharmaceutical, and therapeutic uses)
 RN 393508-47-9 CAPLUS
 CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 2001:31461 CAPLUS
 DOCUMENT NUMBER: 134:100770
 TITLE: Preparation of indoline or tetrahydroquinoline derivatives as inhibitors of activated blood coagulation factor X
 INVENTOR(S): Fujimoto, Koichi; Asai, Fumitoshi; Tanaka, Naoki; Matsushashi, Hayao; Sugidachi, Atsuhiko; Tanimoto, Tatsu
 PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan
 SOURCE: PCT Int. Appl., 431 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001002356	A1	20010111	WO 2000-JP4333	20000630
W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2001072662	A2	20010321	JP 2000-197444	20000630
PRIORITY APPLN. INFO.:			JP 1999-187805	A 19990701
OTHER SOURCE(S):			MARPAT 134:100770	
GI				



AB The title compds. I [R1 is hydrogen, optionally substituted alkyl, optionally substituted alkanoyl, optionally substituted alkylsulfonyl, optionally substituted arylsulfonyl, or optionally substituted sulfamoyl; R2 is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted amino, or optionally substituted saturated cyclic amino; R3 and R4 are each hydrogen, halogeno, alkyl, alkoxy, cyano, nitro, hydroxyl, or alkanoyloxy; A is a single bond, alkylene, oxygen, or O(CH₂)_n (wherein n is 1 to 4); T1 = (CH₂)_n; and n is 1 or 2] are prepared 5-(1-Acetimidoethylpiperidin-4-yl)-2-(7-amidinonaphthalen-2-yl)-1-methanesulfonylindoline dihydrochloride in vitro showed IC₅₀ of 3.9 ng/mL against factor Xa. Formulations are given.


IT 319449-72-4P 319449-73-5P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indoline or tetrahydroquinoline derivs. as inhibitors of activated blood coagulation factor X)

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 319449-72-4 CAPLUS
 CN 2-Naphthalenecarboximidamide, 7-[1-(ethylsulfonyl)-2,3-dihydro-5-(4-[1-iminoethyl]-1-piperazinyl)-1H-indol-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 319449-73-5 CAPLUS
 CN 2-Naphthalenecarboximidamide, 7-[1-(ethylsulfonyl)-2,3-dihydro-5-(4-[1-iminoethyl]-1-piperazinyl)-1H-indol-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

IT 319451-50-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of indoline or tetrahydroquinoline derivs. as inhibitors of activated blood coagulation factor X)
 RN 319451-50-8 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-(7-cyano-2-naphthalenyl)-1-(ethylsulfonyl)-2,3-dihydro-1H-indol-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1998:424243 CAPLUS
 DOCUMENT NUMBER: 129:81756
 TITLE: Preparation of N-(piperazinylphenyl) arylsulfonamides as CNS agents
 INVENTOR(S): Bromidge, Steven Mark; King, Francis David; Wyman, Paul Andrian
 PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK; Bromidge, Steven Mark; King, Francis David; Wyman, Paul Andrian
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIKX22
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827081	A1	19980625	WO 1997-EP7159	19971215
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TH, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2275492	AA	19980625	CA 1997-2275492	19971215
AU 9860904	A1	19980715	AU 1998-60904	19971215
AU 729056	B2	20010125		
EP 946539	A1	19991006	EP 1997-954929	19971215
EP 946539	B1	20030813		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
CN 1246116	A	20000301	CN 1997-181816	19971215
BR 9713734	A	20000328	BR 1997-13734	19971215
JP 2001506646	T2	20010522	JP 1998-527347	19971215
NZ 335970	A	20011026	NZ 1997-335970	19971215
AT 247099	E	20030815	AT 1997-954929	19971215
ES 2203831	T3	20040416	ES 1997-954929	19971215
AP 1277	A	20040505	AP 1999-1556	19971215
W: GH, GM, KE, LS, MW, SD, SI, SZ, UG, ZW				
ZA 9711319	A	19990617	ZA 1997-11319	19971217
TW 418205	B	20010111	TW 1997-86119136	19971218
NO 9903003	A	19990618	NO 1999-3003	19990618
MX 9905900	A	20000131	MX 1999-5900	19990621
US 6423717	B1	20020723	US 2000-643200	20000821
US 2003069233	A1	20030410	US 2002-157258	20020529
US 6599904	B2	20030729		

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 129:81756
 GI

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I: P = Ph, naphthyl, a bicyclic heterocyclic ring, a 5-7 membered heterocyclic ring containing 1-4 heteroatoms selected from O, N or S; A = a single bond, C1-6 alkylene, C1-6 alkenylene; R1 = halo, C1-6 alkyl, C3-6 cycloalkyl, etc.; n = 0-6; R2 = H, C1-6 alkyl, aryl C1-6 alkyl; R3 = R5; R3R5 = (CH2)20, (CH2)30; R3R2 = (CH2)2; (CH2)3; R4 = X(CH2)6R6 (wherein X = a single bond, CH2, O, NH, NCI-6 alkyl; p = 0-6; R6 = (un)substituted 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from N, S or O, NR7R8; R7, R8 = H, C1-6 alkyl, aryl C1-6 alkyl; R5 = H, halo, C1-6 alkyl, having CNS activity (selective 5-HT6 receptor antagonistic activity) and therefore useful in the treatment of schizophrenia, Alzheimer's disease and/or depression, were prepared. Thus, reaction of thiophene-2-sulfonyl chloride with 4-methoxy-3-(4-methylpiperazin-1-yl)aniline in Me2CO afforded 84% the title compound II. Some of compds. I showed particularly good selective 5-HT6 receptor antagonistic activity, e.g. compound III showed pKi of > 8.0 at human cloned 5-HT6 receptor.


IT 209481-62-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of N-(piperazinylphenyl) arylsulfonamides as CNS agents)

RN 209481-62-9 CAPLUS
 CN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



IT 209481-61-8P 209481-65-2P 209481-76-5P
 RN 209481-77-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-(piperazinylphenyl) arylsulfonamides as CNS agents)

RN 209481-61-8 CAPLUS
 CN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




Habte

<06/15/2005>


L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 209481-65-2 CAPLUS
CN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-2,3-dihydro-5-methoxy-4-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 209481-76-5 CAPLUS
CN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-2,3-dihydro-5-phenyl-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 209481-77-6 CAPLUS
CN 1H-Indole, 5-chloro-1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-2,3-dihydro-6-(1-piperazinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT